Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents–assessment of adverse events in non‐randomised studies

OJ Storebø, N Pedersen, E Ramstad… - Cochrane Database …, 2018 - cochranelibrary.com
Background Attention deficit hyperactivity disorder (ADHD) is a common
neurodevelopmental disorder in childhood. The psychostimulant methylphenidate is the …

Associations of sleep disturbance with ADHD: implications for treatment

A Hvolby - ADHD Attention Deficit and Hyperactivity Disorders, 2015 - Springer
Attention-deficit/hyperactivity disorder (ADHD) is commonly associated with disordered or
disturbed sleep. The relationships of ADHD with sleep problems, psychiatric comorbidities …

Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder

S Pliszka… - Journal of the American …, 2007 - Elsevier
This practice parameter describes the assessment and treatment of children and
adolescents with attention-deficit/hyperactivity disorder (ADHD) based on the current …

Effects of diet on behaviour and cognition in children

F Bellisle - British Journal of nutrition, 2004 - cambridge.org
Diet can affect cognitive ability and behaviour in children and adolescents. Nutrient
composition and meal pattern can exert immediate or long-term, beneficial or adverse …

Sleep in autism spectrum disorder and attention deficit hyperactivity disorder

K Singh, AW Zimmerman - Seminars in pediatric neurology, 2015 - Elsevier
Sleep problems are common in autism spectrum disorder (ASD) and attention deficit
hyperactivity disorder (ADHD). Sleep problems in these disorders may not only worsen …

A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder

MA Stein, CS Sarampote, ID Waldman, AS Robb… - …, 2003 - publications.aap.org
Objective. OROS methylphenidate HCL (MPH) is a recently developed long-acting stimulant
medication used to treat attention-deficit/hyperactivity disorder (ADHD). This study was …

Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form

R Conley, SK Gupta, G Sathyan - Current medical research and …, 2006 - Taylor & Francis
Background: The osmotic-controlled release oral delivery system, OROS, is an advanced
drug delivery technology that uses osmotic pressure as the driving force to deliver …

Using the ASEBA to screen for callous unemotional traits in early childhood: Factor structure, temporal stability, and utility

MT Willoughby, DA Waschbusch, GA Moore… - … of psychopathology and …, 2011 - Springer
This study evaluated a five-item screening measure of Callous Unemotional (CU) traits
using items drawn from the Preschool Form of the Achenbach System of Empirically Based …

Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder: a scientific statement from …

VL Vetter, J Elia, C Erickson, S Berger, N Blum… - Circulation, 2008 - Am Heart Assoc
Over the past decade, concerns have been raised regarding the safety of a variety of
psychotropic medications in children and adolescents, the appropriate selection of patients …

Open‐label use of placebos in the treatment of ADHD: A pilot study

AD Sandler, JW Bodfish - Child: care, health and development, 2008 - Wiley Online Library
Background This study examined short‐term efficacy, side effects and acceptability of a
placebo treatment procedure designed to maintain children with attention deficit …